|
1
|
Pan S and Chen R: Pathological implication
of protein post-translational modifications in cancer. Mol Aspects
Med. 86:1010972022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y,
Lu B, Fan Y, Liu Z, Chen X, et al: Ubiquitination and
deubiquitination in cancer: From mechanisms to novel therapeutic
approaches. Mol Cancer. 23:1482024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dagar G, Kumar R, Yadav KK, Singh M and
Pandita TK: Ubiquitination and deubiquitination: Implications on
cancer therapy. Biochim Biophys Acta Gene Regul Mech.
1866:1949792023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu J, Zhang C, Xu D, Zhang T, Chang CY,
Wang J, Liu J, Zhang L, Haffty BG, Zong WX, et al: The ubiquitin
ligase TRIM21 regulates mutant p53 accumulation and gain of
function in cancer. J Clin Invest. 133:e1643542023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dewson G, Eichhorn PJA and Komander D:
Deubiquitinases in cancer. Nat Rev Cancer. 23:842–862. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fu X, Ruan X and He J: METTL3-driven
m6A epigenetics in gastric cancer: Unveiling oncogenic
networks and clinical translation from tumorigenesis to therapy
resistance. Cell Biol Toxicol. 41:1322025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
An Y and Duan H: The role of m6A RNA
methylation in cancer metabolism. Mol Cancer. 21:142022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cai M, Li X, Luan X, Zhao P and Sun Q:
Exploring m6A methylation in skin cancer: Insights into molecular
mechanisms and treatment. Cell Signal. 124:1114202024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Q, Huang X, Tong Y, Yong C, Song M,
Chang C, Dong H, Bu F, Yan S, Ying J and Chen J:
N6-Methyladenosine-modified circNEK11 promotes hepatocellular
carcinoma progression via the miR-1236-3p/GPX2 axis. Cancer Sci.
116:3326–3336. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin H, Zhang X, Yang P, Zhang X, Peng Y,
Li D, Yu Y, Wu Y, Wang Y, Zhang J, et al: RNA m6A methylation
orchestrates cancer growth and metastasis via macrophage
reprogramming. Nat Commun. 12:13942021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qian Y, Wang H, Feng Y, Zhang Y, Hu Q, Pan
Z, Zhang X, Xu L, Yin L, Dong G, et al: The
N6-methyladenosine-mediated cLMNB1 degrades FGFR4 to overcome
osimertinib resistance in non-small cell lung cancer. Cell Death
Dis. 16:8182025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu W, Zheng D, Huang X, Wei Z, Wei Z and
Guo W: TRIM17 promotes the progression of osteosarcoma by
regulating PDK1 m6A modification-mediated AKT/mTOR pathway
activation through ubiquitination of FTO. Cell Death Dis.
16:7672025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Zhu C, Huang B and Wang H: The
dual-edged sword: AlkB homolog 5-mediated autophagy regulation in
cancers-molecular mechanisms and therapeutic implications: A
review. Int J Biol Macromol. 321((Pt 1)): 1462272025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu L, Wei J and Liu P: Attacking the
PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment
in human cancer. Semin Cancer Biol. 85:69–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Y, Xu J, Luo H, Meng X, Chen M and
Zhu D: Wnt signaling pathway in cancer immunotherapy. Cancer Lett.
525:84–96. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su Y, Yang G, Chen B, Qian Y, Ma W, Jiang
X, Yu Q, Li Y and Xu L: Enhancement of CAR-T cell efficacy and
persistence via CD30 costimulation and NF-κB signaling. Mol Cancer.
24:2892025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han D, Wang L, Jiang S and Yang Q: The
ubiquitin-proteasome system in breast cancer. Trends Mol Med.
29:599–621. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou F, Li X, Sun Y, Wang Y, Niu K, Gao X,
Zhang J, Chen T, Li Y, Zhao W, et al: USP39 at the crossroads of
cancer immunity: Regulating immune evasion and immunotherapy
response through RNA splicing and ubiquitin signaling. Front
Immunol. 16:16657752025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Z, Lai J, Ma Z, Pan J, Yang C and Fu
R: Targeting the ubiquitin-proteasome system for cancer. MedComm
(2020). 6:e703912025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koo SY, Park EJ, Noh HJ, Jo SM, Ko BK,
Shin HJ and Lee CW: Ubiquitination links DNA damage and repair
signaling to cancer metabolism. Int J Mol Sci. 24:84412023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao X, Li M, Fu Y, Chen C, Chen Y, Xu L,
Bao L, Ma Z, Xu J, Zhou S, et al: PSMD14-mediated PFKFB2
deubiquitination activates H3K27 lactylation to drive cancer
stemness in gastric adenocarcinoma. Cell Death Differ. 33:813–830.
2026. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen D, Zhao Y, Zhang X, Shi X, Liu Y and
Lou G: USP33-mediated stabilization of c-Myc drives glycolytic
reprogramming and promotes ovarian cancer progression. Biochim
Biophys Acta Gen Subj. 1869:1308302025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang R, Shen Y, Zhang Q, Feng X, Liu X,
Huo X, Sun J and Hao J: TRIM21-mediated Sohlh2 ubiquitination
suppresses M2 macrophage polarization and progression of
triple-negative breast cancer. Cell Death Dis. 14:8502023.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li W, Liang L, Liu S, Tang J, Ou S, Yuan
Z, Zhou Y and Yuan X: Inhibin beta A drives colorectal cancer
progression through macrophage M2 polarization and
mitochondria-dependent ferroptosis suppression. Signal Transduct
Target Ther. 10:4202025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen WJ, Chen LH, Wang J, Wang ZT, Wu CY,
Sun K, Ding BY, Liu N and Xu RX: LHPP impedes energy metabolism by
inducing ubiquitin-mediated degradation of PKM2 in glioblastoma. Am
J Cancer Res. 11:1369–1390. 2021.PubMed/NCBI
|
|
26
|
Li YT, Li KY, Tao SS, Wang T, Lu Y, Chen
H, Zhan YQ, Zhao K, Xiang SS, Li JJ, et al: USP13 stabilizes NLRP3
to facilitate inflammasome activation by preventing TRIM31-mediated
NLRP3 ubiquitination and degradation. Sci Adv. 11:eadx38272025.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu W, Zhou L, Le Y, He Y, Zhou J, Zhang
H, Zhan J, Hu T, Wang J, Lin Y, et al: UCHL3 depletion inhibits
gastric cancer progression and enhances palbociclib sensitivity by
regulating the AKT/CCND1 signaling axis via ENO1 ubiquitination.
Cell Death Dis. 16:8502025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Pu W, Zheng Q, Ai M, Chen S and Peng
Y: Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol
Cancer. 21:992022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Wang Z, Zhong C, Zhang H, Liu R, An
P, Ma Z, Lu J, Pan C, Zhang Z, et al: P53 upregulation by
USP7-engaging molecular glues. Sci Bull (Beijing). 69:1936–1953.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guenette RG, Yang SW, Min J, Pei B and
Potts PR: Target and tissue selectivity of PROTAC degraders. Chem
Soc Rev. 51:5740–5756. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Snyder LB, Neklesa TK, Willard RR, Gordon
DA, Pizzano J, Vitale N, Robling K, Dorso MA, Moghrabi W, Landrette
S, et al: Preclinical evaluation of bavdegalutamide (ARV-110), a
novel PROteolysis TArgeting chimera androgen receptor degrader. Mol
Cancer Ther. 24:511–522. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gough SM, Flanagan JJ, The J, Andreoli M,
Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K,
Bortolon E, et al: Oral estrogen receptor PROTAC Vepdegestrant
(ARV-471) Is highly efficacious as monotherapy and in combination
with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+
Breast cancer models. Clin Cancer Res. 30:3549–3563. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai XS, Dong B, Xu L and Yang ZM:
Synthesis of two versions of carbon-14-labeled ARV-110: An androgen
receptor PROTAC degrader for prostate cancer. J Labelled Comp
Radiopharm. 68:e41542025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Basnet J, Rezq S, Huffman AM, Asala TE,
Yanes Cardozo LL and Romero DG: Androgen receptor PROTAC ARV-110
ameliorates metabolic complications in a mouse model of polycystic
ovary syndrome. Endocrinology. 166:bqaf0912025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zammit CM, Nadel CM, Lin Y, Koirala S,
Ahani E, Potts PR and Nomura DK: Covalent destabilizing degrader of
AR and AR-V7 in androgen-independent prostate cancer cells. J Am
Chem Soc. 147:20512–20524. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ferrero JM, Gal J, Mograbi B and Milano G:
PROTACs and glues: Striking perspectives for engineering cancer
therapy À La Carte. Pharmaceuticals (Basel). 18:13972025.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Surka C, Jin L, Mbong N, Lu CC, Jang IS,
Rychak E, Mendy D, Clayton T, Tindall E, Hsu C, et al: CC-90009, a
novel cereblon E3 ligase modulator, targets acute myeloid leukemia
blasts and leukemia stem cells. Blood. 137:661–677. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zuo X, Liu G, Guo J and Wang Y: Unveiling
the role of m6A modification in esophageal cancer: A new frontier
in tumor innate interferon immunity. Cancer Cell Int. 25:4122025.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen YN, Zhu S, Sun LJ, Zhou RR, Zheng R,
Li XF, Li LY, Sun SJ, Zhao YX, Huang C, et al: Unveiling the
dynamics and therapeutic potential of m(6)A methyltransferases and
demethylases in liver diseases. Int J Biol Sci. 21:6252–6269. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Y, Corovic M, Hoch-Kraft P, Meiser N,
Mesitov M, Körtel N, Back H, Naarmann-de Vries IS, Katti K, Obrdlík
A, et al: m6A sites in the coding region trigger
translation-dependent mRNA decay. Mol Cell. 84:4576–4593. e122024.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang HT, Qian SY, Di PR, Jin CC and Pu
QH: Hypoxia-mediated m(6)A modulation in hepatocellular carcinoma:
A comprehensive review. J Transl Med. 23:12162025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang X, Zhao BS, Roundtree IA, Lu Z, Han
D, Ma H, Weng X, Chen K, Shi H and He C: N(6)-methyladenosine
modulates messenger RNA translation efficiency. Cell.
161:1388–1399. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yuan F, Zhang W, Xia Y, Zhou X and Gao H:
The role and mechanism of METTL3 in cancer: Emerging insights into
m6A methylation and therapeutic potential. Eur J Med Res.
30:10172025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen X, Pu S, Lian K, Li L and Jiang X:
m6A RNA modification in tumor-associated macrophages: Emerging
roles in cancer immunity. Front Immunol. 16:16933362025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Altalbawy F, Azzam ER, Alkhathami A, Hussn
A, Malathi H, Bhatt A, Shankhyan A, Nayak PP, Almalki S and Alnajar
MJ: Epitranscriptomic sculpting: The role of m(6)A in alternative
splicing, cancer progression, and methodological insights. Med
Oncol. 42:4922025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pádua D, Mesquita P and Almeida R: The
epitranscriptomic landscape of gastric cancer stem cells: The
emerging role of m(6)A RNA modifications. Cancers (Basel).
17:35892025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen Z, Hu Y, Jin L, Yang F, Ding H, Zhang
L, Li L and Pan T: The emerging role of N6-methyladenosine RNA
methylation as regulators in cancer therapy and drug resistance.
Front Pharmacol. 13:8730302022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu S, Liu J, Chen S, Li B and Ye Z: M(6)A
methylation in tumor immune microenvironment: Multidimensional
mechanism and targeted therapy strategies. Biochim Biophys Acta Rev
Cancer. 1880:1894892025. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang YF, Wang ZH, Zhang ZC, Tan J, Li ZX,
Yin HZ, Piao XJ, Dai ZH, Mu CY, Wang SJ, et al: YTHDF1 regulates
YTHDF2 stability via m6A-dependent mechanisms in hepatocellular
carcinoma: Insights from in vitro, in vivo, and multi-cohort
clinical studies. J Gastrointest Oncol. 16:2225–2244. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
He PC and He C: m(6) A RNA methylation:
From mechanisms to therapeutic potential. EMBO J. 40:e1059772021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun M, Wang M, Gao H, Li L, Wu M, Li Q, Bu
F, Dong H, Han J, Ying J and Chen J: The interplay between
post-transcriptional RNA regulation and Wnt/β-Catenin signaling in
cancer: A Review. Int J Biol Macromol. 328((Pt 2)): 1476572025.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qin S, Mao Y, Wang H, Duan Y and Zhao L:
The interplay between m6A modification and non-coding RNA in cancer
stemness modulation: Mechanisms, signaling pathways, and clinical
implications. Int J Biol Sci. 17:2718–2736. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q,
Deng S and Zhou H: Signaling pathways in cancer-associated
fibroblasts and targeted therapy for cancer. Signal Transduct
Target Ther. 6:2182021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu L, Wang R, Cheng K, Bai C, Ji Y, Zhang
Y, Yang H, Gong M, Xie F, Zhao Y, et al: Steroid receptor
coactivator-1 facilitates METTL3-mediated m6A modification by
coactivating NF-κB and promotes the malignant progression of
glioblastoma. Oncogene. 44:3333–3349. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wei J, Zhao X, Wang H, Wang C, Liu X, Shan
Z, Guo Y, Gu X, Li R and Zhu Z: STAT1 and m(6)A-mediated IL15RA
upregulation promotes metastasis via ZEB1/NF-κΒ axis in ccRCC. Sci
Rep. 15:379902025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chun H and Baima K: Unraveling the dual
role of METTL3-mediated m(6)A RNA modification in bladder cancer:
Mechanisms, therapeutic vulnerabilities, and clinical implications.
Cancer Biol Ther. 26:25450572025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wu J, Liu L, Xu B, Wang R, Ma W and Deng
J: FTO enhances OSCC progression via m6A-dependent
stabilization of PKM2 mRNA through YTHDF2 modulation. Head Face
Med. 21:712025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H,
Wu M, Liang Y, Zhu F, Zhang Y, Zhang X, et al: The m(6)A
methyltransferase METTL3 promotes bladder cancer progression via
AFF4/NF-κB/MYC signaling network. Oncogene. 38:3667–3680. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang J, Tan L, Jia B, Yu X, Yao R, OUYang
N, Yu X, Cao X, Tong J, Chen T, et al: Downregulation of m(6)A
reader YTHDC2 promotes the proliferation and migration of malignant
lung cells via CYLD/NF-κB pathway. Int J Biol Sci. 17:2633–2651.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
He Y, Sun MM, Zhang GG, Yang J, Chen KS,
Xu WW and Li B: Targeting PI3K/Akt signal transduction for cancer
therapy. Signal Transduct Target Ther. 6:4252021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zang S, Ouyang Y, Li P and Yin X:
Hypothalamic FTO upregulates BDNF to promote GnRH expression
through the PI3K/Akt pathway, leading to precocious puberty. Front
Endocrinol (Lausanne). 16:16653912025. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B,
Li C, Sun L, Qin J, Xu T, et al: METTL14-mediated
N6-methyladenosine modification of SOX4 mRNA inhibits tumor
metastasis in colorectal cancer. Mol Cancer. 19:1062020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li P, Shi Y, Gao D, Xu H, Zou Y, Wang Z
and Li W: ELK1-mediated YTHDF1 drives prostate cancer progression
by facilitating the translation of Polo-like kinase 1 in an m6A
dependent manner. Int J Biol Sci. 18:6145–6162. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li Y, Huang Z, Huang X, Lin W, Ding Q, Fu
W, Chen R, Lai J, Wang J, Liu Q and Qiu S: PXDN regulated by
WTAP/YTHDF1-mediated m(6)A modification activates PI3K/AKT
signaling pathway through extracellular matrix remodeling to
promote progression in nasopharyngeal carcinoma. J Exp Clin Cancer
Res. 45:212025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yi Q, Zhong K, Chen Z, Ouyang X, Zhu W,
Liang L and Zhong J: m6A-modified circMELK regulates
nasopharyngeal carcinoma progression via a
YTHDF1/circMELK-miR-4775-HMGA2 feedback loop. Mol Immunol.
193:50–67. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang P, Chen S, Lei M, Chen Y, He H, Chen
P, Chen W, Zhou H, Wang F and Zhang D: METTL3-mediated m6A
methylation of LncRNA DUXAP8 promoted esophageal squamous cell
carcinoma progression by activating the PI3K/AKT signaling pathway.
Cell Div. 21:12025. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Qin S, Chen K, Chen S, Chen X, Hu Y, Peng
W, Pan Z, Ji X, Pang P, Luo Q and Liu W:
N6-methyladenosine-modified circDCP2 promotes carbon black
nanoparticle-induced malignancy in human bronchial epithelial cells
via PI3K-AKT pathway and macrophage homeostasis. J
Nanobiotechnology. 23:5552025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lai S, Yu L, Sun L, Zheng H, Lu T, Li Z,
Chen C, Wei Y and Wen W: Integrated m6A methylome and transcriptome
profiling of mRNAs and lncRNAs in nasal mucosal epithelial cells of
allergic rhinitis patients undergoing allergen-specific
immunotherapy. Clin Epigenetics. Apr 19–2026.(Epub ahead of print).
View Article : Google Scholar
|
|
69
|
Singhal C, Upadhyaya G, Rajkumar MS, Modak
A, Sethi V, Singh S, Das D, Jain M and Gangappa SN: CUL3(LRB) E3
ubiquitin ligases control thermosensory growth in Arabidopsis by
differentially regulating HY5 and PIF4 protein stability. Sci Adv.
12:eaec78172026. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Collotta G, Gatti M, Ungureanu IM, van
Ackeren V, Rannou E, Vivalda F, Gomez Vieito D, Fishwick KM, von
Aesch C, Porro A, et al: USP7 deubiquitinase stabilizes FAN1 to
support DNA crosslink repair and suppress CAG repeat expansion. Nat
Commun. 17:35512026. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ulianova YA, Ghassah M, Kachaev ZM,
Lebedeva LA and Shidlovskii YV: The conserved network of NF-κB
transcriptional partners from drosophila to mammals. J Mol Biol.
438:1695722026. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xiao Y, Lei Y, He Q, Zeng T and Ling H:
Mechanistic insights and therapeutic potential of E3 ubiquitin
ligases in gastric cancer development. Biochem Biophys Res Commun.
803:1533402026. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wei CH, Weng CW, Wu CY, Chen HY, Chang YH,
Chang GC and Chen JJW: E3 ligase TRIM8 suppresses lung cancer
metastasis by targeting MYOF degradation through K48-linked
polyubiquitination. Cell Death Dis. 16:882025. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gao L, Zhang W, Shi XH, Chang X, Han Y,
Liu C, Jiang Z and Yang X: The mechanism of linear ubiquitination
in regulating cell death and correlative diseases. Cell Death Dis.
14:6592023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Strickson S, Emmerich CH, Goh ETH, Zhang
J, Kelsall IR, Macartney T, Hastie CJ, Knebel A, Peggie M, Marchesi
F, et al: Roles of the TRAF6 and Pellino E3 ligases in MyD88 and
RANKL signaling. Proc Natl Acad Sci USA. 114:E3481–e3489. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Fontana F, Giannitti G, Marchesi S and
Limonta P: The PI3K/Akt pathway and glucose metabolism: A dangerous
liaison in cancer. Int J Biol Sci. 20:3113–3125. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang W, Shi B, Cong R, Hao M, Peng Y, Yang
H, Song J, Feng D, Zhang N and Li D: RING-finger E3 ligases
regulatory network in PI3K/AKT-mediated glucose metabolism. Cell
Death Discov. 8:3722022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang K, Liu J, Li YL, Li JP and Zhang R:
Ubiquitination/de-ubiquitination: A promising therapeutic target
for PTEN reactivation in cancer. Biochim Biophys Acta Rev Cancer.
1877:1887232022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Guo Y, Li Q, Zhao G, Zhang J, Yuan H, Feng
T, Ou D, Gu R, Li S, Li K and Lin P: Loss of TRIM31 promotes breast
cancer progression through regulating K48- and K63-linked
ubiquitination of p53. Cell Death Dis. 12:9452021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Nag JK, Appasamy P, Malka H, Sedley S and
Bar-Shavit R: New Target(s) for RNF43 regulation: Implications for
therapeutic strategies. Int J Mol Sci. 25:80832024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Hsu SH, Tsai YL, Wang YT, Shen CH, Hung
YH, Chen LT and Hung WC: RNF43 inactivation enhances the B-RAF/MEK
signaling and creates a combinatory therapeutic target in cancer
cells. Adv Sci (Weinh). 11:e23048202024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang YT, Liu TY, Shen CH, Lin SY, Hung CC,
Hsu LC and Chen GC: K48/K63-linked polyubiquitination of ATG9A by
TRAF6 E3 ligase regulates oxidative stress-induced autophagy. Cell
Rep. 38:1103542022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhou B, Luo Y, Bi H, Zhang N, Ma M, Dong
Z, Ji N, Zhang S, Wang X, Liu Y, et al: Amelioration of
nonalcoholic fatty liver disease by inhibiting the deubiquitylating
enzyme RPN11. Cell Metab. 36:2228–2244.e7. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Shi Y, Liu B, Zhang Y, Zhao S, Zuo L, Pu
J, Zhai H, Mu D, Du J, Cheng Y, et al: YTHDF1/RNF7/p27 axis
promotes prostate cancer progression. Cell Death Dis. 16:3142025.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ebadi P, Stratton CM and Olsen SK: E3
ubiquitin ligases in signaling, disease, and therapeutics. Trends
Biochem Sci. 50:960–976. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhao L, Kang M, Liu X, Wang Z, Wang Y,
Chen H, Liu W, Liu S, Li B, Li C, et al: UBR7 inhibits HCC
tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis. J
Exp Clin Cancer Res. 41:3302022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhao Y, Huang J, Zhao K, Li M and Wang S:
Ubiquitination and deubiquitination in the regulation of
N(6)-methyladenosine functional molecules. J Mol Med (Berl).
102:337–351. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zeng ZC, Pan Q, Sun YM, Huang HJ, Chen XT,
Chen TQ, He B, Ye H, Zhu SX, Pu KJ, et al: METTL3 protects METTL14
from STUB1-mediated degradation to maintain m(6) A homeostasis.
EMBO Rep. 24:e557622023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Han H, Li Z, Feng Y, Song H, Fang Z, Zhang
D, Yuan D and Shi J: Peptide degrader-based targeting of METTL3/14
improves immunotherapy response in cutaneous melanoma. Angew Chem
Int Ed Engl. 63:e2024073812024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Li Y, Luo B, Lin X, Bai D, Li L, Gao D, Li
X, Zhong X, Wei Y, Yang L, et al: 20(R)-Panaxatriol enhances
METTL3-mediated m(6)A modification of STUB1 to inhibit autophagy
and exert antitumor effects in triple-negative breast cancer cells.
Phytomedicine. 130:1555372024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Du Y, Hou G, Zhang H, Dou J, He J, Guo Y,
Li L, Chen R, Wang Y, Deng R, et al: SUMOylation of the m6A-RNA
methyltransferase METTL3 modulates its function. Nucleic Acids Res.
46:5195–5208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Xia W, Wang X, Li J, Zhang M, Lu J, Li H,
He Q, Meng Q and Huang B: Melatonin mitigates ovarian aging through
regulation of the YTHDF2/m (6)A/UBE3C axis. Acta Biochim Biophys
Sin (Shanghai). 57:1529–1538. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Shi Y, Wang J, Cheng Q, Wu S, Qin X and
Yang Z: UBE3C promotes pancreatic ductal adenocarcinoma progression
by catalysing p53 ubiquitination. Mol Biol Rep. 52:6332025.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Chen YG, Chen R, Ahmad S, Verma R, Kasturi
SP, Amaya L, Broughton JP, Kim J, Cadena C, Pulendran B, et al:
N6-Methyladenosine modification controls circular RNA Immunity. Mol
Cell. 76:96–109.e9. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang X, Yang J, Wen Y, Liu Q, Dou L and
Gao C: METTL3-mediated m(6)A modification promotes FOXO3 expression
and anthracycline resistance in acute myeloid leukemia cells
through autophagy regulation. Nan Fang Yi Ke Da Xue Xue Bao.
45:470–478. 2025.(In Chinese). PubMed/NCBI
|
|
96
|
Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M,
Ma J and Wu L: YTHDF2 destabilizes m(6)A-containing RNA through
direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun.
7:126262016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Li S, Zhou J, Wang S, Yang Q, Nie S, Ji C,
Zhang X, Li S, Zhou X, Chu J, et al: N(6)-methyladenosine-regulated
exosome biogenesis orchestrates an immunosuppressive pre-metastatic
niche in gastric cancer peritoneal metastasis. Cancer Commun
(Lond). 45:941–965. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Huang X, Zhang J, Cun Y, Ye M, Ren Z, Guo
W, Ma X, Liu J, Luo W, Sun X, et al: Spatial control of m(6)A
deposition on enhancer and promoter RNAs through co-acetylation of
METTL3 and H3K27 on chromatin. Mol Cell. 85:1349–1365.e10. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Lavergne G and Roignant JY: DDX21: The
link between m(6)A and R-loops. Mol Cell. 84:1631–1632. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhao Y, Zhou Y, Qian Y, Wei W, Lin X, Mao
S, Sun J and Jin J: m(6)A-dependent upregulation of DDX21 by
super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression
of acute myeloid leukaemia. Clin Transl Med. 14:e16282024.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Li Y, Xia L, Tan K, Ye X, Zuo Z, Li M,
Xiao R, Wang Z, Liu X, Deng M, et al: N(6)-Methyladenosine
co-transcriptionally directs the demethylation of histone H3K9me2.
Nat Genet. 52:870–877. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lv S, Zhang J, Peng X, Liu H, Chu T, Liu
Z, Duan K, Guo J, Wang J, Liu Y and Wei F:
Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A
modification of MEKK1 promote the progression of PDAC.
Theranostics. 15:9922–9943. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Qiu Y, Man C, Zhu L, Zhang S, Wang X, Gong
D and Fan Y: R-loops' m6A modification and its roles in cancers.
Mol Cancer. 23:2322024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Lin K, Zhou E, Shi T, Zhang S, Zhang J,
Zheng Z, Pan Y, Gao W and Yu Y: m6A eraser FTO impairs gemcitabine
resistance in pancreatic cancer through influencing NEDD4 mRNA
stability by regulating the PTEN/PI3K/AKT pathway. J Exp Clin
Cancer Res. 42:2172023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Shen J, Yang H, Qiao X, Chen Y, Zheng L,
Lin J, Lang J, Yu Q and Wang Z: The E3 ubiquitin ligase TRIM17
promotes gastric cancer survival and progression via controlling
BAX stability and antagonizing apoptosis. Cell Death Differ.
30:2322–2335. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Chen L and Mei S: UBE2C, Regulated by
n6-methyladenosine Methyltransferase METTL3, Is an oncogene in
retinoblastoma via PI3K-AKT pathway. DNA Cell Biol. 44:436–444.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zhang ZF, Lok CN and Che CM: Anti-cancer
binuclear gold(I) complexes with mixed bis(N-heterocyclic carbene)
and bis(diphenylphosphino)carborane ligands inhibit thioredoxin
reductase and engage ubiquitin-conjugating enzyme E2 C UBE2C in
lung cancer cells. J Inorg Biochem. 281:1133242026. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ou X, Tan Y, Xie J, Yuan J, Deng X, Shao
R, Song C, Cao X, Xie X, He R, et al: Methylation of GPRC5A
promotes liver metastasis and docetaxel resistance through
activating mTOR signaling pathway in triple negative breast cancer.
Drug Resist Updat. 73:1010632024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Fang D, Ou X, Sun K, Zhou X, Li Y, Shi P,
Zhao Z, He Y, Peng J and Xu J: m6A modification-mediated lncRNA
TP53TG1 inhibits gastric cancer progression by regulating CIP2A
stability. Cancer Sci. 113:4135–4150. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang A, Huang H, Shi JH, Yu X, Ding R,
Zhang Y, Han Q, Ni ZY, Li X, Zhao R and Zou Q: USP47 inhibits
m6A-dependent c-Myc translation to maintain regulatory T cell
metabolic and functional homeostasis. J Clin Invest.
133:e1693652023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang J, Xiu M, Wang J, Gao Y and Li Y:
METTL16-SENP3-LTF axis confers ferroptosis resistance and
facilitates tumorigenesis in hepatocellular carcinoma. J Hematol
Oncol. 17:782024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Liang YL, Zhong CR, Wu JY, Lin ZJ, Lin Z,
Yi TJ, Chen ZP, Jin HL, Yu JD, Lin ZY, et al: USP10 promotes cell
proliferation and gemcitabine resistance in pancreatic cancer by
the regulation of IGF2BP3-STEAP3. Oncogene. 45:383–397. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang X, Zhang Y, Yang X, Fan Y and Zhu Y:
Mechanism of YTHDF2-Mediated epigenetic modification in the
proliferation and invasion of renal cell carcinoma cells.
Biofactors. 52:e700992026. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhou B, Lin Z, Guo Y, Xin W, Ding J, Tang
W and Zhang H: USP22 in human cancers: Mechanistic insights and
inhibitor development. Eur J Med Chem. 312:1188652026. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Chen Y, Liu F, Pal S and Hu Q:
Proteolysis-targeting drug delivery system (ProDDS): Integrating
targeted protein degradation concepts into formulation design. Chem
Soc Rev. 53:9582–9608. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
You L, Wang Q, Zhang T, Xiao H, Lv M, Lv
H, Deng L, Zhang X and Zhang Y: USP14-IMP2-CXCL2 axis in
tumor-associated macrophages facilitates resistance to anti-PD-1
therapy in gastric cancer by recruiting myeloid-derived suppressor
cells. Oncogene. 44:2413–2426. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang J, Guo X, Chen Y, Zhang W, Ren J and
Gao A: RNA m6A reader YTHDF3/UBE2G2 m6A methylation/ACSL4
ubiquitination axis facilitated cell ferroptosis to mediate benzene
hematotoxicity and the protective effect of melatonin. Ecotoxicol
Environ Saf. 305:1192572025. View Article : Google Scholar : PubMed/NCBI
|
